StreetInsider.com News Articles

Form 4 Roivant Sciences Ltd. For: Oct 20 Filed by: Venker Eric

Thu, 22 Oct 2026 18:44:00 -0400

si-local-file:///var/storage/secattach/20261022/27223691.html

Roivant Sciences climbs on positive uveitis trial data

Wed, 21 Oct 2026 10:13:47 -0400

Roivant Sciences stock rose 6.8% in morning trading on Wednesday after the company and its subsidiary Priovant Therapeutics reported that brepocitinib met all primary and key secondary endpoints in two Phase 3 trials for non-infectious uveitis.

The drug, already approved by the FDA under the brand name LISRAYA for dermatomyositis, was evaluated in the CLARITY-1 and CLARITY-2 trials. Patients who received brepocitinib showed a median time to treatment failure that exceeded 48 weeks in both studies. Those on placebo had a median time of approximately 12 weeks. The results reached high statistical significance.

Priovant plans to submit a supplemental New Drug Application

Roivant Sciences stock surges on positive uveitis trial data

Wed, 21 Oct 2026 08:51:54 -0400

Investing.com -- Roivant Sciences Ltd (NASDAQ:ROIV) shares jumped 9% in premarket trading Wednesday after the company announced brepocitinib met all Phase 3 endpoints in trials for non-infectious uveitis.

Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints in both CLARITY-1 and CLARITY-2, the two identical Phase 3 trials evaluating the treatment in NIU, according to a press release issued on October 21, 2026.

The CLARITY program enrolled 371 patients across the two studies. Median time to treatment failure for brepocitinib patients was greater than 48 weeks in both studies,

Roivant Sciences stock surges on positive uveitis trial data

Wed, 21 Oct 2026 08:51:54 -0400

The CLARITY program enrolled 371 patients across the two studies. Median time to treatment failure for brepocitinib patients was greater than 48 weeks in both studies,

Form 8-K Roivant Sciences Ltd. For: Oct 21

Wed, 21 Oct 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20261021/27212933.html

Roivant's brepocitinib meets all phase 3 endpoints in eye disease trial

Wed, 21 Oct 2026 07:00:59 -0400

Roivant Sciences (Nasdaq: ROIV) and Priovant Therapeutics announced positive results from two identical Phase 3 trials evaluating brepocitinib in non-infectious uveitis (NIU), a form of ocular inflammation that can lead to permanent vision loss.

Brepocitinib 45 mg once-daily met the primary endpoint in both the CLARITY-1 and CLARITY-2 studies, which together enrolled 371 patients. The primary endpoint measured time to treatment failure from Week 6 through Week 48. The median time to treatment failure for patients on brepocitinib exceeded 48 weeks in both studies, compared with approximately 12 weeks for patients on placebo (p<0.0001 in both studies).

The cumulative incidence of treatment

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)